Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2026 12:26 ET | Source: Knight Therapeutics

Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been recognized on two of The Globe and Mail’s Report on...
March 23, 2026 08:36 ET | Source: Knight Therapeutics

Knight Amends Normal Course Issuer Bid

MONTREAL, March 23, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by...
March 19, 2026 07:30 ET | Source: Knight Therapeutics

Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

Delivered record-high revenues, Adjusted EBITDA1, Adjusted EBITDA per share1 since inceptionGenerated record high cash flow from operations since inceptionProvides 2026 revenues guidance of $490...
March 17, 2026 07:30 ET | Source: Knight Therapeutics

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
March 17, 2026 07:30 ET | Source: Knight Therapeutics

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate,...
March 12, 2026 07:30 ET | Source: Knight Therapeutics

Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call

MONTREAL, March 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end...
February 18, 2026 07:30 ET | Source: Knight Therapeutics

Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

MONTREAL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
December 18, 2025 07:30 ET | Source: Knight Therapeutics

Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris

MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has...
November 06, 2025 07:30 ET | Source: Knight Therapeutics

Knight Therapeutics Reports Third Quarter 2025 Results

Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Knight...
October 31, 2025 17:15 ET | Source: Knight Therapeutics

Knight Announces Closing of US$100 Million Revolving Credit Facility

MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has...